Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Purchases $2,000,000.00 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock in a transaction that occurred on Wednesday, June 24th. The stock was acquired at an average cost of $8.00 per share, with a total value of $2,000,000.00. Following the completion of the purchase, the director owned 18,379,186 shares in the company, valued at approximately $147,033,488. This represents a 1.38% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $8.00 per share, with a total value of $199,200.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han purchased 210,000 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Performance

Shares of BNR opened at $9.82 on Friday. The company has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The company’s 50 day moving average price is $12.35 and its 200 day moving average price is $19.96. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Crcm LP raised its holdings in shares of Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Marshall Wace LLP acquired a new position in Burning Rock Biotech during the fourth quarter worth $220,000. Prospera Financial Services Inc increased its position in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BNR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. Wall Street Zen downgraded Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.